To elucidate the transport system by which [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) is taken up into the liver, we investigated the uptake characteristics of Z-335 in isolated rat hepatocytes. In addition, we estimated the hepatic uptake of Z-335 in intact rats under steady-state conditions and compared it with the in vitro uptake clearance. Uptake of Z-335 is highly concentrative (cell-to-medium concentration ratios were 21.2 at 0.5 min and 71.7 at 5 min), temperature-dependent, and sensitive to metabolic inhibitors, indicating that uptake is mediated by energydependent uphill transport. In the presence of metabolic inhibitors [carbonyl cyanide p-trifluoromethoxyphenylhydrazone and rotenone], uptake remained at 37 and 49% of the control value, respectively, suggesting that ATP-independent uptake contributes to the total uptake of Z-335. The concentration dependence of the initial uptake velocity indicated a two-component process, one saturable component, with a K m value of 45.6 M and a V max value of 4.1 nmol/min/mg of protein, and a nonspecific diffusion clearance, with a P dif value of 8.3 l/min/mg of protein. The contribution of the carrier-mediated uptake to the total uptake in a linear range was estimated as 91%. The in vivo hepatic intrinsic clearance (CL int, app ) was comparable with that in vitro uptake clearance (PS influx ) and indicated that the CL int, app of Z-335 at steady state is rate-limited by the uptake process. In conclusion, hepatic intrinsic clearance of Z-335 at steady state is rate-limited by the uptake process since Z-335 is efficiently taken up by an active transport mechanism, followed by metabolism or biliary excretion.
Z-335
1 is a new orally active thromboxane A 2 (TXA 2 ) receptor antagonist, which is in phase II of clinical trials. Z-335 inhibits the specific binding of [ 3 H]SQ-29548 to human platelets and also inhibits human platelet aggregation induced by the thromboxane A 2 receptor agonist U-46619. Z-335 ameliorates experimental thrombosis without prolonging bleeding time (Tanaka et al., 1998a,b) . These observations suggest that the target organ of Z-335 is the intravascular compartment (platelet) and that the pharmacological action of Z-335 will be regulated by the plasma concentration of the drug. In rats, Z-335 exhibits concentrative uptake into liver and is eliminated by biliary excretion (Kawabata et al., 1999) . In addition, on the pharmacokinetic study in healthy male volunteers, recovery of the unchanged drug in the urine within 24 h is minimal. These results indicate that Z-335 would be mainly taken up into liver, followed by metabolism or biliary excretion.
Hepatic elimination is one of the major pathways involved in detoxification of xenobiotics, and hepatic uptake is the initial process for the elimination of xenobiotics mediated by metabolism or biliary excretion. Recently, the molecular mechanism underlying the hepatocellular uptake of organic anions has been clarified. In these studies, sodium/taurocholate cotransporting polypeptide (ntcp) and organic anion transporting polypeptide 1 (oatp1) have been cloned as transporters responsible for the Na ϩ -dependent uptake of bile acids and Na ϩ -independent uptake of organic anions, respectively (Meier, 1995) . Furthermore, oatp2 and oatp4 have been identified as homologs of oatp1 (Noé et al., 1997; Cattori et al., 2000) . On the other hand, in human liver, OATP-A (Kullak- Ublick et al., 1995) , OATP-B, (Tamai et al., 2000) , liver-specific organic anion transporter (LST-1/ OATP-2, OATP-C; Abe et al., 1999; Hsiang et al., 1999; Tamai et al., 2000) and OATP-8 (König et al., 2000) have also been identified as homologs of oatp1.
It has been suggested that these transporters are responsible for a large proportion of the hepatic uptake of endogenous and/or exogenous organic anions. In addition, we must consider the drug-drug interactions on the uptake process when these transporters regulate the hepatic elimination of xenobiotic compounds. Therefore, clarifying the contribution of these transporters to the elimination pathways of xenobiotic compounds is important.
To elucidate the transport system that mediates Z-335 uptake into the liver, we investigated the uptake characteristics of Z-335 in dependence of the initial uptake velocity of Z-335 was measured at 0, 27, and 37°C. Uptake experiments in the absence of Na ϩ were performed by replacing the Na ϩ in the medium by choline. The effects of cellular ATP concentration were measured by adding FCCP (2 M) or rotenone (30 M) to the incubation medium.
Determination of Kinetic Parameters. The kinetic parameters for Z-335 uptake were estimated according to the following equation:
where v 0 is the initial uptake velocity of Z-335 (nanomoles per minute per milligram of protein), S is the Z-335 concentration in the medium (micromolar), K m is the Michaelis constant (micromolar), V max is the maximum uptake velocity (nanomoles per minute per milligram of protein), and P dif is the nonspecific uptake clearance (microliters per minute per milligram of protein). The above equation was fit to the uptake data sets by a nonlinear least-squares method using a MULTI program (Yamaoka et al., 1981) to obtain estimates of kinetics parameters. The inhibition constants (K i ), assuming competitive inhibition, were calculated according to the following equation from the data obtained by varying the inhibitor concentration (I; estradiol 17␤-glucuronide was added at 0.5, 1, 5, 10, 50, 100, and 500 M, and all other inhibitors were added at 1, 5, 10, 50, 100, 500, and 1000 M in incubation medium) with the Z-335 concentration kept constant (5 M).
where the mean K m (45.6 M) and V max (4.1 nmol/min/mg of protein) values obtained from parallel experiments (Fig. 3) were used for the K i calculation. Estimation of Hepatic Uptake Clearance Extrapolated from the in Vitro Data and in Vivo Hepatic Clearance for Z-335. Based on the kinetic parameters obtained by the fitting procedure described, the permeabilitysurface product (PS influx ) (milliliters per minute per 250-g rat) was calculated with the following equation:
where 1 g of liver ϭ 1.25 ϫ 10 8 cells (␣) (Lin et al., 1980) , 1 mg of protein ϭ 1 ϫ 10 6 cells (␤), and the 250-g rat ϭ 11.1 g of liver (␥) (Sugita et al., 1982) . The in vivo hepatic clearances (CL h, well , CL h, PT ) were estimated from these values by using a well stirred model (eq. 4) (Wilkinson and Shand, 1975; Pang and Rowland, 1977) and a parallel-tube model (eq. 5) (Bass, 1980) .
where the measured plasma protein unbound fraction (f u ) and blood/plasma concentration ratio (Rb) are 0.01 and 0.57, respectively, and the hepatic blood flow rate (Q) in rats is 14.8 ml/min/250-g of rat (Dedrick et al., 1973) . The total body clearance (CL tot ) based on in vivo infusion data was calculated according to the following equation:
where I rate is the infusion rate of Z-335 and C a, ss is the arterial plasma concentration of Z-335 at 60 min after starting the infusion. The total hepatic elimination rate at steady state (V h ), hepatic clearance (CL h ), and the apparent hepatic intrinsic clearance (CL int, app ) were calculated from the following equations:
where C hv, ss is the hepatic venous plasma concentration of Z-335 at 60 min after starting the infusion. (Fig. 3 ) indicated a two-component process. The estimated kinetic parameters (mean Ϯ S.E.) were as follows: K m ϭ 45.6 Ϯ 5.2 M, V max ϭ 4.1 Ϯ 1.2 nmol/min/mg of protein, and P dif ϭ 8.3 Ϯ 4.8 l/min/mg of protein (Table 1) .
Effect of Temperature and Metabolic Inhibitors on the Initial Uptake Velocity of Z-335. The initial uptake velocity of Z-335 exhibited marked temperature dependence; the uptake decreased to 19% at 0°C and to 45% at 27°C. Rotenone, an inhibitor of mitochondrial respiration, and FCCP, an oxidative phosphorylation uncoupler, significantly decreased the uptake of Z-335. Open circles represent apparent C/M ratio (the cellular uptake amount divided by the extracellular Z-335 concentration). Each point and vertical bar give mean Ϯ S.E. from nine determinations in three separate preparations.
FIG. 3. Concentration dependence of Z-335 uptake by isolated rat hepatocytes.
The relationship between initial uptake velocity (v 0 ) and concentration of Z-335 in the incubation medium. Each open circle and vertical bar represent mean Ϯ S.E. from three different preparations. The solid line is the least-square fit of date to eq. 1. The dotted line represents nonspecific diffusion calculated with value of nonspecific uptake clearance (P dif ). Closed circles, which were calculated by subtracting nonspecific diffusion from total uptake (open circles), represent saturable uptake. Dashed line is theoretical curve of saturable uptake.
FIG. 4. Effect of metabolic inhibitors on initial uptake of [ 14 C]Z-335.
Each point and vertical bar represent mean Ϯ S.E. of four determinations. Hepatocytes were preincubated at 37°C for 3 min. At time 0, the metabolic inhibitor (2 M FCCP, open circles; 30 M rotenone, closed circles) was added. At the time indicated, the initial uptake was determined.
FIG. 5. Eadie-Hofstee Plot of sodium-dependent and -independent uptake of [ 14 C]Z-335 into isolated rat hepatocytes.
Each point and vertical bar represent mean Ϯ S.E. from three different preparations. Isolated rat hepatocytes were incubated in sodium-containing medium (open circles) or choline-containing medium (sodium replaced by choline, closed circles) during the uptake experiment. (Fig. 4) . Na ؉ Dependence of Z-335 Uptake into Isolated Rat Hepatocytes. The Na ϩ dependence of Z-335 uptake was studied by replacing the Na ϩ in the medium by choline. Eadie-Hofstee plots for Z-335 uptake in Na ϩ -or choline-containing medium are shown in Fig. 5 . When sodium was replaced by choline, the estimated kinetic parameters (mean Ϯ S.E.) were as follows: K m ϭ 35.8 Ϯ 5.4 M, V max ϭ 2.3 Ϯ 0.4 nmol/min/mg protein, and P dif ϭ 7.3 Ϯ 3.5 l/min/mg of protein. Consequently, replacement of sodium by choline did not significantly decrease uptake (Table 1) .
Inhibition of the Initial Uptake Velocity of Z-335 by Organic Anions, Bile Acids, Organic Cations, and Neutral Compounds. To investigate the specificity of Z-335 uptake, the effects of other substrates on the uptake of Z-335 were studied. Z-335 uptake was decreased by the addition of estradiol 17␤-glucuronide, estrone 3-sulfate, taurocholate, cholate, and glycocholate, with K i values of 9.3, 31.0, 47.3, 43.0, and 60.2 M, respectively (Fig. 6, A and B ; Table 2 ).
The inhibitory effects of pravastatin and BSP on Z-335 uptake were also observed, with K i values of 52.9 and 7.0 M, respectively ( Fig.  6C ; Table 2 ). In addition, inhibitory effects of quinidine, quinine, and pancuronium on Z-335 uptake were observed, with K i values of 65.7, 57.2, and 280.0 M, respectively ( Fig. 6D; Table 2 ). Furthermore, Z-335 uptake was inhibited by the addition of probenecid, with a K i value of 67.6 M. The inhibition of Z-335 uptake by digoxin (a neutral compound), ibuprofen, and cimetidine (classified as a type I organic cation; Nakamura et al., 1994) was also estimated. Digoxin, ibuprofen, and cimetidine had slight effects on Z-335 uptake at relatively higher concentrations, with K i values of 161.3, 159.9, and 752.0 M, respectively ( Table 2) .
Extrapolation of in Vivo Clearance from in Vitro Uptake Parameters. The in vivo clearance parameters were calculated by using eqs. 6, 7, 8, and 9. CL tot , CL h , and CL int, app were estimated to be 3.0, 2.8, and 315.7 ml/min/250-g rat, respectively (Table 3) . Furthermore, PS influx in a 250-g rat was extrapolated from the in vitro uptake parameters (eq. 3). CL h, well and CL h, PT , based on PS influx , were also
FIG. 6. Inhibition of [ 14 C]Z-335 (5 M) uptake by conjugated steroids (A), bile acids (B), organic anions(C), and organic cations (D).
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dmd.aspetjournals.org calculated by using a well stirred model (eq. 4) and a parallel-tube model (eq. 5). The extrapolated PS influx was 132.3 ml/250-g rat, and thus CL h, well and CL h, PT were calculated to be 1.2 and 1.3 ml/min/ 250-g rat, respectively (Table 3) .
Discussion
The uptake of Z-335 is highly concentrative (C/M ratios were 21.2 at 30 s and 71.7 at 5 min), temperature-dependent, and sensitive to metabolic inhibitors, suggesting an energy-dependent uphill transport. In a previous article, the intracellular ATP concentration was decreased rapidly to Ͻ8% at 30 min by addition of FCCP (2 M) or rotenone (30 M) (Yamazaki et al., 1993) . In the presence of metabolic inhibitors, despite the decreased cellular ATP, uptake remained at 37% (FCCP) and 49% (rotenone) of the control value, respectively. Organic anion transporting polypeptides (e.g., oatp1 and oatp2) have been reported to transport endogenous and exogenous substrates by an ATP-independent transport system, and it was suggested that oatp1 and oatp2 are glutathione exchangers (Li et al., 1998 (Li et al., , 2000 . These findings may be relevant to our observation that ATP-independent uptake contributes a part of the total uptake of Z-335. Furthermore, the concentration dependence of initial uptake velocity (Fig. 3) indicated a two-component process, one saturable component, with a K m value of 45.6 M and a V max value of 4.1 nmol/min/mg of protein, and a nonspecific diffusion clearance, with a P dif value of 8.3 l/ min/mg of protein. The contribution of the carrier-mediated uptake to the total uptake [(V max /K m )/(V max /K m ϩ P dif. )] was estimated to be 91%, and therefore, the uptake of Z-335 into liver would occur mainly by the carrier-mediated uptake system. Sodium/taurocholate cotransporting polypeptide (ntcp) has been identified in rat liver and is expressed in rat hepatocyte sinusoidal membranes (Stieger et al., 1994) . In our study, when the Na ϩ in the medium was replaced by choline, the V max value was reduced slightly, but uptake clearance (V max /K m ϩ P dif. ) remained at approximately 70% of that in Na ϩ -containing medium. This finding suggests that the contribution of Na ϩ -dependent uptake was slight and that Z-335 is taken up into liver mainly by an Na ϩ -independent uptake system. The system responsible for the uptake of Z-335 was investigated by the addition of conjugate steroids (e.g., estradiol 17␤-glucuronide and estrone 3-sulfate), bile acids (e.g., taurocholate, cholate, and glycocholate), and exogenous organic anions (e.g., pravastatin and BSP) to the incubation medium. Previously, it has been suggested that hepatic uptake of these substrates is mediated by oatp1, oatp2, and oatp4 (Meier, 1995; Noé et al., 1997; Tokui et al., 1999; Cattori et al., 2000) . The uptake of Z-335 was inhibited by these substrates, with K i values similar to their K m values, suggesting that Z-335 shares a common carrier protein with these substrates and might also be taken up via organic anion transport systems, such as oatp1, oatp2, and oatp4. Furthermore, the K i value of digoxin, which is specifically transported Eckhardt et al. (1999) .
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e Mean Ϯ S.E. of five rats, calculated from data in in vivo infusion study (at steady state) by use of eq. 6. by oatp2 (Noé et al., 1997) , for Z-335 uptake was 161.3 M, considerably higher than the K m value of digoxin (expression system for oatp2, 0.24 M; Noé et al., 1997; hepatocytes, 0.695 M; Hedman and Meijer, 1998) , indicating that Z-335 and digoxin are taken up by different carrier proteins. Therefore, the contribution of oatp2 to the uptake of Z-335 would be negligible.
In transport measurements with isolated hepatocytes, more hydrophobic organic cations, such as quinidine, quinine, and cyanine 863, have previously been classified as type II cations (Groothuis and Meijer, 1996) . In addition, it has been postulated that these cations are transported by a transport system different from that involved in transport of type I organic cations, such as tetraethylammonium and choline (Elferink et al., 1995) . Furthermore, a cation transporter (rOCT1) has been sequenced from a cDNA library of rat kidney (Gründemann et al., 1994) and is expressed in the basolateral membranes of renal proximal tubules and in the sinusoidal membranes of hepatocytes (Koepsell, 1998) . In hepatocytes, rOCT1 transports type I cations across the basolateral membrane, whereas type II cations are taken up by a different transport system (Nagel et al., 1997) . van Montfoort et al. (1999) demonstrated that type II cations were transported by rat oatp1, oatp2, and human OATP, whereas type I cations were not transported by these systems. The uptake of Z-335 was inhibited by quinidine, quinine, and pancuronium, which are classed as type II cations, with estimated K i values of 65.7, 57.2, and 280.0 M, respectively. Furthermore, the inhibitory effect of cimetidine, a type I cation (Nakamura et al., 1994) , on the uptake of Z-335 was slight, with a K i value (752.0 M) 20 times the K m value of cimetidine uptake (32 M; Nakamura et al., 1994) . Furthermore, Hedman and Meijer (1998) reported that quinidine and quinine exhibited a stereoselective inhibitory effect on the hepatic uptake of digoxin and that quinine was more potent than quinidine as an inhibitor of digoxin uptake. However, stereoselective inhibition of Z-335 uptake by quinidine and quinine was not observed in our study. In addition, the weak inhibition by digoxin supports a slight involvement of oatp2.
Recently, Sugiyama et al. (2001) demonstrated that probenecid was nonselective inhibitor for oatp1, 2, oat1, and oat3 transfectants in LLC-PK1 cells. In addition, taurocholate was a selective inhibitor for the oatp family. The uptake of Z-335 was inhibited significantly by probenecid, with a K i value of 67.6 M, and taurocholate. Taken together, the data suggest that Z-335 uptake might involve the oatp family, possibly oatp1, and not the oat family.
After Z-335 is taken up into rat liver, it has been mainly metabolized to taurine conjugate. Also, Z-335 and its metabolite are mainly eliminated by biliary excretion. Accurate evaluation of hepatic clearance is very important for predicting the pharmacological effect and/or side effects of this drug. Therefore, in this study, the hepatic distribution of Z-335 at steady state was directly evaluated by measuring the plasma concentration in both arterial and hepatic venous blood. In addition, the rate-limiting process involved in hepatic elimination of Z-335 was also examined by comparison of the in vivo apparent hepatic intrinsic clearance (CL int, app ), with the kinetic parameters obtained from isolated hepatocytes. The total body clearance (CL tot ) at steady state was estimated to be 3.0 ml/min/250-g rat, and CL tot was similar to hepatic clearance (CL h ) (2.8 ml/min/250-g rat). Furthermore, the calculated CL int, app for Z-335 was 315.7 ml/min/ 250-g rat (Table 3) . On the other hand, based on in vitro parameters, the calculated PS influx was 132.3 ml/min/250-g rat, which was comparable to CL int, app . These results indicate that only the influx process influences CL int, app ; therefore, hepatic intrinsic clearance of Z-335 at steady state is rate-limited by the uptake process.
In conclusion, hepatic intrinsic clearance of Z-335 at steady state is rate-limited by the uptake process since Z-335 is efficiency taken up by an active transport mechanism, probably involving oatp1 and/or oatp4, followed by metabolism or biliary excretion.
